Biocept, Inc. (BIOC) News

Biocept, Inc. (BIOC): $2.91

-0.06 (-2.02%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter BIOC News Items

BIOC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BIOC News Highlights

  • For BIOC, its 30 day story count is now at 4.
  • Over the past 17 days, the trend for BIOC's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • BIVI are the most mentioned tickers in articles about BIOC.

Latest BIOC News From Around the Web

Below are the latest news stories about Biocept Inc that investors may wish to consider to help them evaluate BIOC as an investment opportunity.

Biocept reports increase in COVID-19 RT-PCR testing due to Omicron

Biocept (BIOC) said the COVID-19 RT-PCR testing volume has increased in 2022 with the emergence of the Omicron variant.The company has received more than 40K samples for COVID-19…

Seeking Alpha | January 21, 2022

Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant

SAN DIEGO, January 21, 2022--Biocept has received more than 765,000 samples for RT-PCR COVID-19 testing since June 2020.

Yahoo | January 21, 2022

Has Biocept, Inc. (BIOC) Outpaced Other Medical Stocks This Year?

Here is how Biocept, Inc. (BIOC) and BioVie Inc. (BIVI) have performed compared to their sector so far this year.

Yahoo | January 7, 2022

Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10

SAN DIEGO, January 04, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022. A webcast of the Biocept presentation can be accessed on the Investor Relations section of the company website beginning on January 10, 2022 at 7:00 a.m. Eastern time.

Yahoo | January 4, 2022

Biocept (NASDAQ:BIOC) Raised to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Biocept (NASDAQ:BIOC) from a hold rating to a buy rating in a research note issued to investors on Monday morning, Zacks.com reports. The brokerage currently has $4.25 price objective on the medical research companys stock. According to Zacks, Biocept, Inc. is a commercial stage oncology diagnostics company. It has []

Transcript Daily | December 24, 2021

Biocept (NASDAQ:BIOC) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Biocept (NASDAQ:BIOC) from a hold rating to a buy rating in a report released on Monday, Zacks.com reports. Zacks Investment Research currently has $4.25 price target on the medical research company’s stock. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms […] The post Biocept (NASDAQ:BIOC) Upgraded at Zacks Investment Research appeared first on ETF Daily News .

ETF Daily News | December 23, 2021

Biocept (NASDAQ:BIOC) Downgraded by Zacks Investment Research

Zacks Investment Research downgraded shares of Biocept (NASDAQ:BIOC) from a buy rating to a hold rating in a report issued on Friday morning, Zacks.com reports. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing […]

Dakota Financial News | December 13, 2021

Biocept (NASDAQ:BIOC) Stock Rating Upgraded by Zacks Investment Research

Biocept (NASDAQ:BIOC) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued on Thursday, Zacks.com reports. The brokerage currently has a $4.75 price objective on the medical research companys stock. Zacks Investment Researchs price target indicates a potential upside of 21.17% from the companys current price. []

Transcript Daily | December 11, 2021

Biocept (NASDAQ:BIOC) Upgraded to Buy at Zacks Investment Research

Biocept (NASDAQ:BIOC) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Thursday, Zacks.com reports. The brokerage currently has a $4.75 target price on the medical research companys stock. Zacks Investment Researchs price objective points to a potential upside of 18.45% from the companys []

Dakota Financial News | December 9, 2021

Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain

SAN DIEGO, December 09, 2021--SABCS Spotlight Presentation shows that Biocept's CNSide CSF assay identifies actionable HER2 mutations in metastatic breast cancer.

Yahoo | December 9, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.529 seconds.